Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 1

A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function

Bristol-Myers Squibb · NCT07763418

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–84 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 1
Target enrollment
30
US sites recruiting
3
Study start
September 8, 2026
Record last updated
October 1, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to assess the pharmacokinetics and safety of golcadomide (BMS-986369) in matched healthy participants with normal renal function, adult participants with severe renal impairment, and participants with end-stage renal disease.

Being studied: Golcadomide

Conditions: Kidney Failure, Chronic

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Participant must have severe renal impairment (RI).
  • Participant must have end-stage renal disease (ESRD).
  • Participant must be healthy male and female participants not of childbearing potential between 18 and 84 years of age (inclusive) with a BMI between 18 and 40 kg/m2, (inclusive) at screening.

Exclusion Criteria

  • Any surgical or medical condition possibly affecting drug absorption, distribution, metabolism, and excretion (ADME).
  • Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study
  • Known or suspected active autoimmune disorder, or any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status
  • Other protocol-defined inclusion/exclusion criteria apply.

Recruiting US locations

  • Arizona Clinical Trials - Chandler

    Chandler, AZ 85225

    Site contact: Anita Kohli, Site 0003 · 434-825-0921

  • Panax Clinical Research

    Miami Lakes, FL 33014

    Site contact: Robert Perry, Site 0002 · 305-698-4500

  • Orlando Clinical Research Center OCRC

    Orlando, FL 32809-3017

    Site contact: Thomas Marbury, Site 0001 · 407-257-3462

Study contacts (from the official record)

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
  • First line of the email MUST contain NCT # and Site #.
All healthy volunteers studies in Arizona →
A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide… (NCT07763418) | Bored Studies